The Clinical Observation Of EGFR-TKI Combined With Radiotherapy In Patients With Advanced Stage Non-small Cell Lung Cancer

Purpose:To evaluate the effectiveness and toxicity of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)combined with radiotherapy for the treatment of advanced non-small cell lung cancer(NSCLC).Methods:A retrospective analysis of 72 non-small cell lung cancer patients in IIIb-IV stages with clinical data from January 2013 to December 2014 in the First Hospital of Jilin university.All patients have been genetic tested with EGFR mutations.According to the treatment methods,the patients were divided into synchronous treatment and single drug groups.We compared recent treatment effect,progression-free survival and adverse reactions in the patients of two groups.Results:The total effective rate(CR + PR)was 79.41%,and the local control rate(CR + PR+ SD)was 94.12% in the patients of synchronous treatment group;the total effective rate(CR + PR)was 44.74%,and the local control rate(CR + PR + SD)was 94.74% in the patients of single drug group(P <0.05).Karnofsky performance status in the synchronous treatment group was better than that in the single drug group(90 points,90 points)3 months after treatment(P < 0.05).There were no significantly statistical difference at rest time points in two groups.The median progression-free survival(PFS)in two groups was 12.5 and 10 months,respectively(P <0.05).The patients for 6 months > PFS in the synchronous treatment group were 30 cases(93.75%),those for 1 year > PFS were 17(53.13%).The patients for 6 months > PFS in the single drug group were 31 case(88.57%),those for 1 year > PFS were 11 case(31.43%).There was no serious adverse reaction in the patients of two groups.Conclusion:The better curative effect for the patients with advanced-stage NSCLC in the near future can be got with EGFR-TKI treatment combined with radiotherapy,which improve the quality of life of the patients.As compared that with only EGFR-TKI therapy,the progression free survival in the patients extend with EGFR-TKI treatment combined with radiotherapy,and no serious adverse reaction happened.